About Elbion
Elbion is a company based in Radebeul (Germany) founded in 2002 was acquired by Biotie in November 2008. Elbion has raised $45 million across 1 funding round from investors including 3i Group, Biotie and Burrill and Company. Elbion has completed 1 acquisition, including DrugAbuse Sciences.
- Headquarter Radebeul, Germany
- SectorsHealthcare
- Website elbion.com
- Social LinkedIn
- Acquired by Biotie (Nov 2008)
Funding Insights of Elbion
Elbion has successfully raised a total of $45M through 1 strategic funding round. The most recent funding activity was a Series A round of $45 million completed in January 2005. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $45M
- Total Rounds 1
- Last Round Series A — $45M
- First Round $45M
(Jan 2005)
- Investors Count 3
All 1 funding rounds of Elbion with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2005 | $45M | Series A | – | – |
4 investors in total: 4 institutional.
Investors in Elbion
Elbion has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include 3i Group, Biotie and Burrill and Company.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm focused on mid-market businesses | 1945 | 3i.com | London, United Kingdom | |
Multi-category products are listed on an online B2B platform. | 1994 | burrillandco.com | Wuxi, China | |
- | – | dvcg.de | - | |
Drugs for neurodegenerative and psychiatric disorders are developed by Biotie. | 1998 | biotie.com | Turku, Finland |
Investor details for Elbion
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Elbion
Elbion has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include DrugAbuse Sciences.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapies for alcohol and drug addictions are developed and commercialized. | drugabusesciences.com | Menlo Park, United States | 1994 | Jan 2007 | •••• |
Complete acquisition details for Elbion
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Elbion
4 dated milestones of Elbion across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Elbion is founded.
- Funding First funding round of $45.0M.
- Acquisition Acquires DrugAbuse Sciences.
- Exit Acquired by Biotie.
Latest news on Elbion
Complete news archive for Elbion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Elbion
10 companies that operate in the same segment as Elbion (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Elbion
Elbion was founded in 2002 and raised its 1st funding round 3 years after it was founded.
Elbion is headquartered in Radebeul, Germany. It is registered at Radebeul, Saxony, Germany.
Elbion is a funded company, having raised a total of $45M across 1 funding round to date. The company's 1st funding round was a Series A of $45M, raised on Jan 2005.
Elbion was focussed on the discovery of small molecules against inflammatory and CNS diseases. Its drug discovery activities were focused on PDE inhibitors, adenosine antagonists and potassium channel modulators. It was co-developing its lead product, AWD 12-281 along with GSK for COPD and for atopic dermatitis. It was also developing ELB139, a subunit-specific GABA(A) agonist for the anxiety disorders and ELB353 for inflammatory diseases. In October 2008, Biotie acquired Elbion.
Elbion has made 1 acquisition, including DrugAbuse Sciences.
Elbion has 4 investors. Key investors include 3i Group, Biotie, Burrill and Company, and Deutsche Venture Capital.
Yes. Elbion was acquired by Biotie in November 2008.